Skip to main content
Top
Published in: PharmacoEconomics 6/2001

01-06-2001 | Leading Article

Developing Guidance for Budget Impact Analysis

Authors: Mr Paul Trueman, Michael Drummond, John Hutton

Published in: PharmacoEconomics | Issue 6/2001

Login to get access

Abstract

The role of economic evaluation in the efficient allocation of healthcare resources has been widely debated. Whilst economic evidence is undoubtedly useful to purchasers, it does not address the issue of affordability which is an increasing concern. Healthcare purchasers are concerned not just with maximising efficiency but also with the more simplistic goal of remaining within their annual budgets. These two objectives are not necessarily consistent.
This paper examines the issue of affordability, the relationship between affordability and efficiency and builds the case for why there is a growing need for budget impact models to complement economic evaluation. Guidance currently available for such models is also examined and it is concluded that this guidance is currently insufficient. Some of these insufficiencies are addressed and some thoughts on what constitutes best practice in budget impact modelling are suggested. These suggestions include consideration of transparency, clarity of perspective, reliability of data sources, the relationship between intermediate and final end-points and rates of adoption of new therapies. They also include the impact of intervention by population subgroups or indications, reporting of results, probability of re-deploying resources, the time horizon, exploring uncertainty and sensitivity analysis, and decision-maker access to the model. Due to the nature of budget impact models, the paper does not deliver stringent methodological guidance on modelling. The intention was to provide some suggestions of best practice in addition to some foundations upon which future research can build.
Literature
1.
go back to reference Mason J, Drummond M. Cost effective league tables and priority setting. In: Drummond M, Maynard A, editors. Purchasing and providing cost effective health care. Edinburgh: Churchill Livingstone, 1993: 109–25 Mason J, Drummond M. Cost effective league tables and priority setting. In: Drummond M, Maynard A, editors. Purchasing and providing cost effective health care. Edinburgh: Churchill Livingstone, 1993: 109–25
2.
3.
go back to reference Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on the preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995 Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on the preparation of submissions to the pharmaceutical benefits advisory committee. Canberra: Commonwealth Department of Human Services and Health, 1995
4.
go back to reference Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health, 1994 Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Ontario: Ministry of Health, 1994
5.
go back to reference NHS Executive. Faster access to modern treatment. How NICE appraisal will work: a discussion paper. Leeds: NHS Executive, 1999 NHS Executive. Faster access to modern treatment. How NICE appraisal will work: a discussion paper. Leeds: NHS Executive, 1999
6.
go back to reference Ziekenfondsraad. Dutch guidelines for pharmacoeconomic research. Amsterdam: Ziekenfondsraad, 1999 Ziekenfondsraad. Dutch guidelines for pharmacoeconomic research. Amsterdam: Ziekenfondsraad, 1999
7.
go back to reference Infarmed. Methodological guidelines for economic evaluation studies of medications. Lisbon, Portugal: Infarmed, 1999 Infarmed. Methodological guidelines for economic evaluation studies of medications. Lisbon, Portugal: Infarmed, 1999
8.
go back to reference Ministry of Social Affairs and Health. Guidelines for the preparation of an account of health economic aspects [unofficial translation]. Helsinki: Ministry of Social Affairs and Health, 1999 Ministry of Social Affairs and Health. Guidelines for the preparation of an account of health economic aspects [unofficial translation]. Helsinki: Ministry of Social Affairs and Health, 1999
9.
go back to reference Norwegian Medicines Control Authority, Department of Economics. Norwegian guidelines for pharmacoeconomic analysis in connection with application for reimbursement. Oslo: Department of Pharmacoeconomics, Norwegian Medicines Control Agency, 1999 Norwegian Medicines Control Authority, Department of Economics. Norwegian guidelines for pharmacoeconomic analysis in connection with application for reimbursement. Oslo: Department of Pharmacoeconomics, Norwegian Medicines Control Agency, 1999
10.
go back to reference Drummond MF, Dubois D, Garrattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 1999; 2 (5): 323–32PubMedCrossRef Drummond MF, Dubois D, Garrattini L, et al. Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 1999; 2 (5): 323–32PubMedCrossRef
11.
go back to reference Langley PC, Sullivan SD. Pharmacoeconomic evaluations: guidelines for drug purchasers. J Manage Care Pharm 1996; 2: 671–7 Langley PC, Sullivan SD. Pharmacoeconomic evaluations: guidelines for drug purchasers. J Manage Care Pharm 1996; 2: 671–7
12.
go back to reference Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997 Standing Medical Advisory Committee. The use of statins. London: Department of Health, 1997
13.
go back to reference Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9 Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9
14.
go back to reference Freemantle N, Barbour R, Johnson R, et al. The use of statins: a case of misleading priorities? BMJ 1997; 315: 826–8PubMedCrossRef Freemantle N, Barbour R, Johnson R, et al. The use of statins: a case of misleading priorities? BMJ 1997; 315: 826–8PubMedCrossRef
15.
go back to reference Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322–5PubMedCrossRef Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000; 321: 1322–5PubMedCrossRef
16.
17.
go back to reference Pelen F. Reimbursement and pricing of drugs in France: an increasingly complex system. Health Econ Prev Care 2000; 0 (0): 19–22 Pelen F. Reimbursement and pricing of drugs in France: an increasingly complex system. Health Econ Prev Care 2000; 0 (0): 19–22
18.
go back to reference Duthie T, Trueman P, McCann C, et al. Research into the use of health economics in decision-making in the United Kingdom — phase II: is health economics ‘for good or evil’. Health Policy 1999; 46: 143–57PubMedCrossRef Duthie T, Trueman P, McCann C, et al. Research into the use of health economics in decision-making in the United Kingdom — phase II: is health economics ‘for good or evil’. Health Policy 1999; 46: 143–57PubMedCrossRef
19.
go back to reference Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275–83PubMedCrossRef
20.
go back to reference Gold MR, Siegel JE, Russell LB, et al., editors. Cost effectiveness in health and medicines. New York (NY): Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al., editors. Cost effectiveness in health and medicines. New York (NY): Oxford University Press, 1996
21.
go back to reference Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1997 Canadian Co-ordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 2nd ed. Ottawa: CCOHTA, 1997
22.
go back to reference National Institute for Clinical Excellence. Appraisal of new and existing technologies: interim guidance for manufacturers and sponsors. London: National Institute for Clinical Excellence, 1999 National Institute for Clinical Excellence. Appraisal of new and existing technologies: interim guidance for manufacturers and sponsors. London: National Institute for Clinical Excellence, 1999
23.
go back to reference Mather DB, Sullivan SD, Augustein D, et al. Incorporating clinical outcomes and economic consequences into drug formulary decision: a practical Approach. Am J Manage Care 1999; 5 (3): 277–85 Mather DB, Sullivan SD, Augustein D, et al. Incorporating clinical outcomes and economic consequences into drug formulary decision: a practical Approach. Am J Manage Care 1999; 5 (3): 277–85
24.
go back to reference Langley PC. Guidelines for formulary submissions for pharmaceutical product evaluation. Denver (CO): Blue Cross Blue Shield of Colorado/Blue Cross Blue Shield of Nevada, 1998 Langley PC. Guidelines for formulary submissions for pharmaceutical product evaluation. Denver (CO): Blue Cross Blue Shield of Colorado/Blue Cross Blue Shield of Nevada, 1998
25.
go back to reference Titlow K, Randel L, Clancy C, et al. Drug coverage decisions: the role of dollars and values. Health Aff 2000; 19 (2): 240–7CrossRef Titlow K, Randel L, Clancy C, et al. Drug coverage decisions: the role of dollars and values. Health Aff 2000; 19 (2): 240–7CrossRef
26.
go back to reference Department of Health. The new NHS: modern and dependable. London: Department of Health, 1997 Department of Health. The new NHS: modern and dependable. London: Department of Health, 1997
27.
go back to reference Wilson H, Scott S. PBMA: its role in the future purchasing arrangements for health care services. Health Policy 1995; 33: 157–60PubMedCrossRef Wilson H, Scott S. PBMA: its role in the future purchasing arrangements for health care services. Health Policy 1995; 33: 157–60PubMedCrossRef
28.
go back to reference Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993; 148 (6): 913–7PubMed Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993; 148 (6): 913–7PubMed
Metadata
Title
Developing Guidance for Budget Impact Analysis
Authors
Mr Paul Trueman
Michael Drummond
John Hutton
Publication date
01-06-2001
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119060-00001

Other articles of this Issue 6/2001

PharmacoEconomics 6/2001 Go to the issue

Adis Pharmacoeconomic Drug Evaluation

Torasemide